CSPI on kava
This article was originally published in The Tan Sheet
Executive Summary
FDA's request for healthcare practitioner data linking botanical with hepatotoxicity "in and of itself is not sufficient to protect consumers," Center for Science in the Public Interest says in Jan. 28 letter. Agency should request manufacturers, retailers to temporarily halt sales pending FDA determination of safety issues. "FDA should also issue an advisory to consumers explaining the concerns that have been raised and advise them to consult with their physicians before taking any products that contain kava," group maintains...
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.